TrialCNS drugs2018

A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).

Tim L Wigal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.